Daily Bulletin

Men's Weekly

.

MedAlliance Receives Fourth FDA Breakthrough Device Designation for Sirolimus Drug-Eluting Balloon in Treatment of De Novo Coronary Lesions

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
MedAlliance Receives Fourth FDA Breakthrough Device Designation for Sirolimus Drug-Eluting Balloon in Treatment of De Novo Coronary Lesions

NYON, Switzerland, March 4, 2021 /PRNewswire/ -- MedAlliance, the first drug-eluting balloon (DEB) company in the world to receive US Food and Drug Administration (FDA) Breakthrough Device Designation Status for a sirolimus DEB, has now been awarded breakthrough status for SELUTION SLR™, its sustained limus release DEB catheter, in the...

Read more: MedAlliance Receives Fourth FDA Breakthrough Device Designation for Sirolimus Drug-Eluting Balloon...

Business News

What Businesses Need to Know About Intellectual Property Law

Whether you're launching a startup or growing an established brand, understanding intellectual property law is essential. An intellectual property lawyer in Melbourne can guide you through registrat...

Daily Bulletin - avatar Daily Bulletin

Avoiding the Delays – Why Families Hire Registered Migration Agents for Their Parent Visa Application

For many migrants, bringing in their ageing parents to reside with them in Australia is one of the most significant milestones. However, the visa pathway is not always simple. The daunting prerequisit...

Daily Bulletin - avatar Daily Bulletin

The ultimate checklist for launching a digital-first business

If you’re launching a business in 2025, chances are it’s going to be digital-first. Whether you’re running an online store, offering consulting services, or building something entirely new, they all h...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals